The Prophylactic Antiobiotic Regimens in Tumor Surgery (PARITY)

MSTS is funding (2012-14) the Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): A Pilot Randomized MultiCenter Clinical Trial. The PI is Michelle Ghert, MD and is coordinated by the Center for Evidence-Based Orthopaedics at McMaster University. The trial is an international, multicenter randomized double-blind surgical trial in which patients undergoing endoprosthetic reconstruction of the lower extremity are randomized to either short-term (24 hours) or long-term (5 days) postoperative antibiotics. The primary endpoint is deep infection within the first year following implantation. Investigator orientation occurred this fall and patient accrual has started. Six North American sites have the study open. Five states in the UK (representing well over 100 cases per year) are planning to participate. A site in Buenos Aires is active and we have sites in Japan and Israel 'in the queue' for funding.

Interested in participating? Contact Michelle Ghert, MD via email at, as all MSTS sponsored studies are open to all MSTS members.


2015 Annual Meeting

October 6-10

Orlando, FL

Support MSTS

Learn how you can help support the Musculoskeletal Tumor Society.

For The Patient


 Tumor Information

Become a Member